Budget impact of xanomeline and trospium chloride for the treatment of adults with schizophrenia in the United States

Key Points

• The research aims to assess the budget impact of xanomeline and trospium chloride for treating schizophrenia in the US.
• Analyzed budget impact using per member per month (PMPM) figures over three years
• Assessed market uptake scenarios of 1%, 2%, and 3% for each year
• Evaluated safety and tolerability profiles of xanomeline and trospium chloride
• The budget impact was estimated at $0.0177 PMPM in year 1 and $0.1006 PMPM in year 3
• Findings indicate a favorable cost-effectiveness ratio for inclusion in formularies
• Supports the placement of xanomeline and trospium chloride in US health care plans.